HDAC9 and T-cell non-Hodgkin lymphoma: Although a multitude of drugs acting via HDAC inhibition are currently in clinical trials or in the market, only HDACis, such as vorinostat, romidepsin, and belinostat have been approved for some T-cell lymphomas and Pan for multiple myeloma.